A research programme by the Access to Medicine Foundation
The foundation

Access to Medicine Foundation

The Foundation stimulates and guides pharmaceutical companies to do more to improve access to medicine. It is an independent non-profit organisation.
Our programmes

Access to Medicine Index

Ranks 20 of the world’s largest pharmaceutical companies based on their efforts to address access to medicine, including in strategy, governance, R&D and pricing. By publicly recognising the best performers, the Index spurs companies to compete to be the best.

Antimicrobial Resistance Benchmark

Tracks what the 30 most active companies in antimicrobial R&D and manufacturing are doing to bring antimicrobial resistance under control. By assessing the level of action, it provides a reality check on progress against AMR.

Access to Vaccines Index

Reports what vaccine companies are doing to ensure all children can be immunised wherever they live. By uncovering what is working and where, this Index helps ensure vaccine markets also reach the poorest and most remote communities.
Type search term(s) and press enter
Often searched for
Index Ranking Vacancies 10-year analysis R&D pipelines AMR antibiotics Investors
  • Events
  • Conference: Exane BNP Paribas: ESG Conference 2021
Conference - Event date: 08 Sep 2021
Share

Exane BNP Paribas: ESG Conference 2021

On 8 September 2021, Jayasree K. Iyer, Executive Director of the Access to Medicine Foundation, participated in a fireside chat hosted by Exane BNP Paribas as part of their inaugural ESG Conference.

Explore further

Media

Dozens of institutional investors push for ‘fair and equitable’ Covid-19 response

Ed Silverman of Stat News covers investors' call to action for equitable access to COVID-19 treatments and vaccines. 
Event

Goldman Sachs co-hosted investor launches of the 2021 Access to Medicine Index

On Tuesday 9 March 2021, Goldman Sachs and the Access to Medicine Foundation co-hosted the final of a series of investor launch events on the 2021 Access to Medicine Index. The three events brought together over 250 investors as well as company representatives from Europe, USA and Japan.  
Feature

How investors can use our research

Investors use the Foundation's insights and analysis to better manage risks and opportunities for pharmaceutical companies related to access-to-medicine and antimicrobial resistance, and to inform direct engagements with investee companies.

Get in touch

Back to top |